HomeCompareEPGNY vs MRK

EPGNY vs MRK: Dividend Comparison 2026

EPGNY yields 113.84% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPGNY wins by $6.70M in total portfolio value
10 years
EPGNY
EPGNY
● Live price
113.84%
Share price
$2.39
Annual div
$2.72
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.75M
Annual income
$2,475,584.99
Full EPGNY calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — EPGNY vs MRK

📍 EPGNY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPGNYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPGNY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPGNY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPGNY
Annual income on $10K today (after 15% tax)
$9,676.26/yr
After 10yr DRIP, annual income (after tax)
$2,104,247.24/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, EPGNY beats the other by $2,095,918.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPGNY + MRK for your $10,000?

EPGNY: 50%MRK: 50%
100% MRK50/50100% EPGNY
Portfolio after 10yr
$3.41M
Annual income
$1,242,691.57/yr
Blended yield
36.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EPGNY
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPGNY buys
0
MRK buys
0
No recent congressional trades found for EPGNY or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPGNYMRK
Forward yield113.84%2.76%
Annual dividend / share$2.72$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$6.75M$56.8K
Annual income after 10y$2,475,584.99$9,798.13
Total dividends collected$6.11M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EPGNY vs MRK ($10,000, DRIP)

YearEPGNY PortfolioEPGNY Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$22,084$11,383.83$11,206$366.19+$10.9KEPGNY
2$47,125$23,495.20$12,650$502.35+$34.5KEPGNY
3$97,280$46,856.67$14,407$694.19+$82.9KEPGNY
4$194,489$90,398.69$16,585$967.82+$177.9KEPGNY
5$377,010$168,906.98$19,342$1,363.89+$357.7KEPGNY
6$709,401$306,000.59$22,913$1,947.19+$686.5KEPGNY
7$1,297,177$538,118.21$27,662$2,823.89+$1.27MEPGNY
8$2,307,585$919,605.21$34,159$4,173.35+$2.27MEPGNY
9$3,998,005$1,528,889.11$43,337$6,308.80+$3.95MEPGNY
10$6,753,450$2,475,584.99$56,776$9,798.13+$6.70MEPGNY

EPGNY vs MRK: Complete Analysis 2026

EPGNYStock

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Full EPGNY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this EPGNY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPGNY vs SCHDEPGNY vs JEPIEPGNY vs OEPGNY vs KOEPGNY vs MAINEPGNY vs JNJEPGNY vs ABBVEPGNY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.